In this study, we support the client on assessing cardiotoxicity and identifying the mechanism of action (MOA) through functional and gene expression means. Our hiPSC-derived atrial-like cardiomyocytes (aCMs) and control Ncyte® vCardiomyocytes were manufactured and characterized according to this specific research project. Then, cells were seeded into multi-electrode array (MEA) plates and treated with a panel of control compounds with the aim to identify drug targets, support SAR and determine mechanisms of action.
The results demonstrate the potential of Ncardia's hiPSC-derived models and custom screening services, as a robust and physiologically relevant platform to accelerate and de-risk the development of new therapeutic strategies.